CAD may help highlight nodules the clinician may have otherwise missed, but its use is not without legal ramifications. What do you think? Take this survey.
Computer aided detection (CAD) is increasingly utilized in radiology, and is most prevalent in screening mammography where it is reimbursed by Medicare. While CAD may be helpful to the clinician in highlighting nodules and asymmetric or suspicious breast density the clinician may not have otherwise observed or noted, its use is not without legal ramifications.
Important legal questions associated with the use of CAD include to what extent CAD is becoming the legal standard of care in our subspecialty, and whether radiologists or surgeons now feel obligated to follow or biopsy CAD findings as a component of “defensive medicine,” even if they deem the CAD findings questionable.
Also of legal significance is whether radiologists choose to archive CAD markings. And if they don’t, is there a worry that current or even future, improved versions of CAD might later be used in a courtroom setting to show that findings were “CAD evident,” or alternatively, that discarded CAD findings might be deemed “spoliation” (destruction of evidence).
To better address the legal ramifications of CAD use (and non-use), we are conducting an online survey of diagnostic imagers who perform mammography to better understand the extent to which radiologists are using CAD, and their views on the legal ramifications of CAD use. We suspect there are mixed opinions regarding its current utility, and are curious to see if radiologists have concerns about CAD’s potential legal consequences.
Responses to the survey will remain anonymous. The goal of the survey will be to present data at a national meeting and/or publish it in a radiology related publication. The results will also be shared here with the readers of Diagnostic Imaging.
All clinicians with experience with CAD in mammography are invited to complete the survey at the link below. Thank you for your assistance.
Survey: https://www.surveymonkey.com/s/9MLR6TT
Jonathan L. Mezrich, MD, JD, MBA, LLM, a former practicing attorney, is a third-year radiology resident at the University of Maryland. Eliot Siegel, MD, FACR, FSIIM, is professor of radiology at the University of Maryland School of Medicine Department of Diagnostic Radiology and Nuclear Medicine and chief of imaging for the VA Maryland Healthcare System.
Contrast-Enhanced Mammography and Dense Breasts: What a New Meta-Analysis Reveals
May 1st 2024The 10-study meta-analysis demonstrated that contrast-enhanced mammography has a 95 percent sensitivity rate and an 81 percent specificity rate for diagnosing suspicious lesions in women with dense breasts.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
Mammography-Based AI Abnormality Scoring May Improve Prediction of Invasive Upgrade of DCIS
April 9th 2024Emerging research suggests that an artificial intelligence (AI) score of 75 or greater for mammography abnormalities more than doubles the likelihood of invasive upgrade of ductal carcinoma in situ (DCIS) diagnosed with percutaneous biopsy.